Mumbai-based pharmaceutical company Lupin has reported significant growth in both the US and Indian markets, leading to a 4% surge in its shares. As of 9:26 AM, Lupin shares were trading 4.02% higher at ₹1,987.50.
Financial Highlights
Lupin’s financial performance in the first quarter of FY25 ending on June 30 has been impressive:
- Profit After Tax (PAT): Increased by 77.2% year-on-year (Y-o-Y), reaching ₹801 crore.
- Revenue from Operations: Rose by 16.2% Y-o-Y to ₹5,514.3 crore.
- Sequential Growth: PAT increased by 122.9% compared to the previous quarter, with revenue up by 12.6%.
- EBITDA Margin: Increased by 48.9% Y-o-Y, reaching ₹1,308.8 crore.
Key Drivers
- New product launches
- Strong performance in key markets
| Metric | Q1 FY25 | Y-o-Y Change (%) |
|---|---|---|
| Profit After Tax (PAT) | ₹801 crore | 77.2% |
| Revenue | ₹5,514.3 crore | 16.2% |
| EBITDA Margin | ₹1,308.8 crore | 48.9% |
Lupin’s robust growth in profit and revenue, driven by successful new product launches and strong market performance, has positively influenced its stock price, marking a multi-quarter high margin of 22.2%.
Ahmedabad Plane Crash